June 6, 2022
Category: Corona Virus
Dr. Robert Malone Headwind 2 Episode 1
June 5, 2022
Ivermectin Pushback: Why Would Merck, the Original Patent Holder, Come Out With Safety Concerns?
June 3, 2022
Dr. Tess Lawrie: “So Merck, which has competing drugs to treat COVID and prevent COVID, came out with a statement saying that there’s a concerning lack of safety data. Now, in actual fact, Merck had done the original safety studies, and in 2002, they showed that ivermectin was safe even at 10 times the usual dose, so this was very concerning and clearly a conflicted statement that then began to be used by these health authorities.“
The Moral Obligation to Disrupt the Narrative and Speak Out
June 3, 2022
Prof. Mattias Desmet: “The people who articulate a dissonant voice might not be able to wake up the masses, but that doesn’t mean that their voice has no effect. It has an extremely important effect; it constantly disturbs the mass formation. And that [prevents] the mass formation [from going] so deep that the people in the mass become convinced that they have to eliminate, that they have to destroy the people who do not go along with them.”
Politics and Pandemic Fatigue Doom California’s Covid Vaccine Mandates | Kaiser Health News
May 31, 2022
https://khn.org/news/article/california-politics-covid-vaccine-mandates-pandemic-fatigue/
May the Force Be With Them: Scientists Fight Back
May 31, 2022
Incoming White House COVID Response Coordinator Called Great Barrington Declaration ‘junk science’, Authors ‘clowns’
The Foegen effect: A mechanism by which facemasks contribute to the COVID-19 case fatality rate
Feb 18, 2022
By Fögen, Zacharias MD
Editor(s): Shalaby., Mohammed Nader
CONCLUSION: This study revealed that wearing facemasks might impose a great risk on individuals, which would not be mitigated by a reduction in the infection rate. The use of facemasks, therefore, might be unfit, if not contraindicated, as an epidemiologic intervention against COVID-19. Proving or disproving the “Foegen effect” using experimental studies as described above should be a priority to public health scientists.
NY TIMES: Bioterror Researchers Build A More Lethal Mousepox (Published 2003)
Published Oct 31, 2003
[ Interesting read from nineteen years ago… ]
Scientists have created a highly lethal virus in an effort to develop stronger protections against supervirulent forms of smallpox that terrorists might turn on humans, researchers said yesterday.
The genetic engineering involved a virus known as mousepox, which infects mice but is not known to hurt people. Into that virus the scientists spliced a single gene that made it superlethal, then tested it on mice treated with different combinations of a smallpox vaccine and drugs.
The scientists said the results showed that the best defenses proved quite effective in preventing deadly disease not only in mice, but probably in humans exposed to customized smallpox of similar design.
This type of research has been debated for years, with critics arguing again yesterday that superviruses created in laboratories could inspire terrorists to create their own deadly diseases. The mousepox scientists countered that the research could help deter terrorism by demonstrating the emergence of more potent medical defenses.
The mousepox research was done at St. Louis University as a project financed by the National Institute of Allergy and Infectious Diseases meant to find new protections against smallpox, which kills one in three victims.
Kim Iversen: Pfizer’s Paxlovid Covid REBOUND Problem Is Confusing Scientists
May 17, 2022
Kim Iversen reacts to Stephen Colbert’s Covid diagnosis. The U.S. Food and Drug Administration issued an EUA for the emergency use of Paxlovid for the treatment of mild-to-moderate coronavirus disease 2019 (COVID-19) in adults and pediatric patients with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The 5-day treatment course of PAXLOVID should be initiated as soon as possible after a diagnosis of COVID-19 has been made, and within 5 days of symptom onset. Should a patient require hospitalization due to severe or critical COVID-19 after starting treatment with PAXLOVID, the patient should complete the full 5-day treatment course per the healthcare provider’s discretion. According to clinical trial data, Paxlovid had an 89% reduction in the risk of hospitalization and death. The CDC says the risk for covid increases steadily as you age, and it’s not just those over the age of 65 who are at increased risk for severe illness.